MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development

	
		    SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research,
a global provider of pharmaceutical competitive intelligence and market
research, has published two new reports providing critical strategic
insight for companies developing therapies to treat hematologic
malignancies. These reports are based on primary interviews conducted with
hematology experts from North America immediately following the American
Society of Hematology (ASH) annual meeting.

    The first report, entitled "Thought Leader Insight & Analysis -
AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic
syndrome. "This report highlights the most important data presented at ASH,
and clarifies the ways these data will change clinical practice," according
to Jeff Berk, MedPredict president. "A key emphasis of this report is
transplant, and how pharmaceuticals and biologicals better prepare patients
for transplant. Our thought leader panel discusses how to achieve complete
responses, how they are thinking about combination therapy, and new ways
for attacking quiescent malignant stem cells."

    The second report, entitled "Thought Leader Insight & Analysis -
Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at
ASH is likely to translate into changing treatment paradigms. "This report
brings together the diverse perspectives of experts who grapple with a wide
spectrum of issues related to these hematologic malignancies, including
clinical pathology, community based patients, tertiary care treatment, and
medical oncology from the strategic vantage point of clinical commercial
development," said Berk.

    Topics this report addresses include:



    -- Reimbursement: oral vs. parenteral; induction vs. maintenance.

    -- Multiple myeloma/lymphoma treatment strategies, including:

         - transplant eligible/non-transplant eligible;
         - induction/maintenance;
         - doublets/triplets;
         - community/tertiary care;
         - +65 years old/younger; and
         - approval pathways.
    Companies mentioned in these reports include: Allos, Amgen,
Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics,
Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK, Gloucester,
ImmunoGen, Incyte, Keryx, Mayo Scottsdale, Merck, Nereus, Novartis, PDL
Biopharma, Proteolix, Rigel, Roche, Seattle Genetics, Takeda/Millennium,
Vion, Wyeth, Xencor.

    This report can be purchased by contacting MedPredict
(http://www.medpredict.com).

    About MedPredict

    MedPredict maintains a proprietary database of over 1,000 global
physician thought leaders, including 40+ specialties in 30+ therapeutic
categories. Based on primary interviews with these thought leaders,
MedPredict publishes periodic reports in each category to keep clients
up-to-date on emerging trends and competitive activity. The reports include
thought leader reactions to recent publications and medical conferences, as
well as clinical, regulatory and marketing activity.